-->

Member Access

Registration is free

Bookshelf

Kinase Drug Discovery (Rsc Drug Discovery)

by Richard A. Ward, Frederick Goldberg, David P. Rotella and David E. Thurston

KinaseInhBoook


Available in Dec 2011.

Visit our bookshelf for more books on Kinases and Kinase Inhibitors or pre-order this book today




B&W Powered

KKB Hot Article: Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent. PDF Print E-mail
Written by KKB   
Tuesday, 20 April 2010 19:36
Citation: Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
Authors: Verheijen JC, Richard DJ, Curran K, Kaplan J, Lefever M, Nowak P, Malwitz DJ, Brooijmans N, Toral-Barza L, Zhang WG, Lucas J, Hollander I, Ayral-Kaloustian S, Mansour TS, Yu K, Zask A.
PubMed PMID: 19894727
Abstract: Design and synthesis of a series of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as potent and selective inhibitors of the mammalian target of rapamycin (mTOR) are described. Optimization of the 6-aryl substituent led to the discovery of inhibitors carrying 6-ureidophenyl groups, the first reported active site inhibitors of mTOR with subnanomolar inhibitory concentrations. The data presented in this paper show that 6-arylureidophenyl substituents led to potent mixed inhibitors of mTOR and phosphatidylinositol 3-kinase alpha (PI3K-alpha), whereas 6-alkylureidophenyl appendages gave highly selective mTOR inhibitors. Combination of 6-alkylureidophenyl groups with 1-carbamoylpiperidine substitution resulted in compounds with subnanomolar IC(50) against mTOR and greater than 1000-fold selectivity over PI3K-alpha. In addition, structure based drug design resulted in the preparation of several 6-arylureidophenyl-1H-pyrazolo[3,4-d]pyrimidines, substituted in the 4-position of the arylureido moiety with water solubilizing groups. These compounds combined potent mTOR inhibition (IC(50) < 1 nM) with unprecedented activity in cellular proliferation assays (IC(50) < 1 nM).
Targets: ATR, AURKB, CSNK1G1, FRAP1, MAPK14, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG
Number of SAR data points: 222
Number of Targets: 10
Last Updated on Saturday, 20 August 2011 00:07
 
Copyright © 2012 Kinase Data Portal. All Rights Reserved.
 

KinaseData Forum Latest Posts

No posts to display.

Featured Links:
Apple


B&W Powered

Fight Against Cancer